LaVoie Strategic Communications Group, Inc. Adds Three New Life Science Clients to Growing Roster
Posted on: Monday, 22 May 2006, 06:04 CDT
SWAMPSCOTT, Mass., May 22 /PRNewswire/ -- LaVoie Strategic Communications Group, Inc. (LaVoie Group), a life sciences focused public and investor relations firm, announced today that it has been selected by publicly-traded Javelin Pharmaceuticals of Cambridge, MA, and IBEX Technologies, Inc. of Montreal, Canada, both as agency of record. LaVoie Group also announced that it has been selected to represent privately-held, VisEn Medical, Inc., of Woburn, MA.
To facilitate the growing client demand, LaVoie Group will be expanding its presence with new offices in Salem, Massachusetts and Greenwich, Connecticut.
"LaVoie Group is focused on providing strategic counsel and superior execution to our growing roster of US and international clients. We have aligned ourselves with some of the industry's best development-stage companies who are positioned to become tomorrow's leaders. We look forward to growing with them," said Donna L. LaVoie, President and CEO, LaVoie Group.
About LaVoie Group
LaVoie Group provides senior level strategic counsel and tactical implementation of public, investor and corporate communications programs designed to properly position, create visibility and drive value for each client. Our clients range from start-ups to industry leaders.
About Javelin Pharmaceuticals, Inc.
Javelin (BULLETIN BOARD: JVPH.OB) is a specialty pharmaceutical company, applying innovative, proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, visit http://www.javelinpharmaceuticals.com/.
About IBEX Technologies
IBEX (TSX: IBT) is focused on the development of therapeutics and diagnostics for the management of cancer and arthritis. The Company's cancer program is based on a family of genes known as kallikreins. Its arthritis program is based on a series of biomarkers of collagen degradation and synthesis.
IBEX markets a number of products, including its proprietary enzymes (heparinases and chondroitinases), as well as a series of arthritis and kallikrein-based assays. For more information visit, http://www.ibex.ca/.
About VisEn Medical
VisEn Medical is developing leading edge optical molecular imaging technology platforms for use in animal research and ultimately into clinic research. VisEn's products focus on molecular imaging of central disease states, including oncology, bone growth, cardiovascular disease and inflammation. For further information visit, http://www.visenmedical.com/.
LaVoie Strategic Communications Group, Inc.
CONTACT: Donna L. LaVoie, President & CEO of LaVoie Group,+1-781-596-0200 ext. 103, dlavoie@lavoiegroup.com
Web site: http://www.lavoiegroup.com/
Company News On-Call: http://www.prnewswire.com/comp/133897.html
Source: PRNewswire
Related Articles
- Spherix Incorporated Selects LaVoie Group As Corporate Communications/Public Relations Agency
- LaVoie Group Adds Cardioxyl Pharmaceuticals to Its Client Roster
- Sonitus Medical Secures Strategic Investment and Technology Advancement Agreement From In-Q-Tel
- LaVoie Group Appointed by Mithridion as PR Agency
- LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
- LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
- T2 Biosystems Announces Strategic Investment and Technology Development Agreement With In-Q-Tel
- LaVoie Group Adds Interleukin Genetics to Its Life Science Agency Roster
- LaVoie Group Adds Two New Companies to Its Life Science Client Roster
- LaVoie Group Adds EyeGate Pharma and Molecular Biometrics to Its Life Science Client Roster
 |
 |
User Comments (0)
RSS Feeds